X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (501) 501
Publication (80) 80
Book Review (7) 7
Book Chapter (4) 4
Dissertation (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (298) 298
immunotherapy (265) 265
anti-ctla-4 (261) 261
humans (231) 231
ipilimumab (222) 222
oncology (222) 222
melanoma (192) 192
cancer (172) 172
metastatic melanoma (157) 157
immunology (120) 120
antibodies, monoclonal - therapeutic use (106) 106
anti-ctla-4 antibody (99) 99
animals (95) 95
anti-pd-1 (91) 91
nivolumab (83) 83
female (82) 82
melanoma - drug therapy (82) 82
male (77) 77
antibodies, monoclonal - adverse effects (69) 69
anti-ctla-4 antibodies (68) 68
care and treatment (67) 67
ctla-4 blockade (66) 66
middle aged (66) 66
adverse events (64) 64
blockade (64) 64
ctla-4 antigen - immunology (63) 63
antineoplastic agents - therapeutic use (62) 62
metastasis (61) 61
lymphocytes (60) 60
regulatory t-cells (60) 60
ctla-4 antigen - antagonists & inhibitors (59) 59
t cells (59) 59
therapy (59) 59
ctla-4 (58) 58
tumors (58) 58
mice (57) 57
aged (54) 54
pembrolizumab (54) 54
antigens (52) 52
immune checkpoint (50) 50
chemotherapy (48) 48
anti-ctla-4 therapy (47) 47
immunotherapy - methods (47) 47
melanoma - immunology (47) 47
advanced melanoma (46) 46
cancer-immunotherapy (46) 46
medicine, research & experimental (45) 45
lymphocytes t (44) 44
open-label (43) 43
pd-1 (43) 43
antibodies (42) 42
treatment outcome (41) 41
article (40) 40
monoclonal antibodies (40) 40
survival (40) 40
adult (39) 39
antineoplastic agents - adverse effects (39) 39
immune checkpoint inhibitors (39) 39
antitumor immunity (37) 37
skin neoplasms - drug therapy (36) 36
t-cells (36) 36
analysis (35) 35
antibodies, monoclonal - administration & dosage (35) 35
cytotoxicity (35) 35
neoplasms - immunology (35) 35
dendritic cells (34) 34
medicine & public health (34) 34
research (34) 34
clinical trials (33) 33
melanoma - pathology (33) 33
cell line, tumor (32) 32
checkpoint inhibitors (32) 32
health aspects (32) 32
cancer therapies (31) 31
monoclonal-antibody (31) 31
antibodies, monoclonal - immunology (30) 30
antibody (30) 30
lymphocyte-associated antigen-4 (30) 30
prostate cancer (30) 30
safety (30) 30
ctla-4 protein (29) 29
autoimmune hypophysitis (28) 28
drug therapy (28) 28
immune system (28) 28
aged, 80 and over (27) 27
autoimmunity (27) 27
patients (27) 27
tumor-regression (27) 27
complications and side effects (26) 26
immune checkpoint blockade (26) 26
immune-related adverse events (26) 26
medical research (26) 26
mice, inbred c57bl (26) 26
programmed cell death 1 receptor - antagonists & inhibitors (26) 26
apoptosis (25) 25
ctla-4 antigen (25) 25
hypophysitis (25) 25
management (25) 25
pharmacology & pharmacy (25) 25
toxicity (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (473) 473
French (20) 20
German (6) 6
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 10/2016, Volume 7, Issue 1, p. 13193
A therapeutic strategy that can eliminate primary tumours, inhibit metastases, and prevent tumour relapses is developed herein by combining adjuvant... 
BREAST-CANCER | DENDRITIC CELLS | ANTI-CTLA-4 THERAPY | DRUG-DELIVERY | MULTIDISCIPLINARY SCIENCES | MELANOMA PATIENTS | RECEPTOR T-CELLS | AUTOIMMUNE-DISEASE | CARBON NANOTUBES | ADOPTIVE IMMUNOTHERAPY | VACCINES
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 34, pp. 3815 - 3822
Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 antibody) in patients with... 
ANTIBODIES | SURVIVAL | METASTATIC MELANOMA | MONOTHERAPY | ANTI-CTLA-4 | ONCOLOGY | CANCER | ADVERSE EVENTS | Index Medicus
Journal Article
ANNALS OF THE RHEUMATIC DISEASES, ISSN 0003-4967, 03/2018, Volume 77, Issue 3, pp. 393 - 398
Objectives T o evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs),... 
PEMBROLIZUMAB | MUSCULOSKELETAL | ANTI-CTLA-4 | SAFETY | POLYMYALGIA-RHEUMATICA | DEATH-LIGAND 1 | ANTIBODY | RHEUMATOLOGY | ARTHRITIS | BLOCKADE | ADVERSE EVENTS
Journal Article
BLOOD, ISSN 0006-4971, 08/2014, Volume 124, Issue 7, pp. 1070 - 1080
With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR) T cells has been limited, and CAR T cells have not been... 
EFFECTOR | ANTI-CTLA-4 THERAPY | DISTINCT | CD28 | CANCER-IMMUNOTHERAPY | ANTITUMOR IMMUNITY | MELANOMA PATIENTS | HEMATOLOGY | LINEAGE | CD8(+) T-CELLS | TH17 CELLS
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 04/2017, Volume 44, Issue 4, pp. e70 - e70
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 12/2013, Volume 110, Issue 50, pp. 20212 - 20217
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. Despite... 
APOPTOSIS | SAFETY | MULTIDISCIPLINARY SCIENCES | DEPLETION | ANTIBODY | CD8(+) T-CELLS | TUMOR RESPONSES | ANTI-CTLA-4 | KPC mouse | STROMAL FIBROBLASTS | tumor stroma | tumor immunogenicity | ANTITUMOR IMMUNITY | IPILIMUMAB | T cell exclusion
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 3/2018, Volume 17, Issue 3, pp. 671 - 676
Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose... 
anti CTLA-4 | immunomodulation | phase 1 | Lenalidomide | Ipilimumab
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 1988 - 1995
Background: Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We... 
Anti-PD-1 mAbs | Serum biomarkers | NSCLC | IL-8 | Anti-CTLA-4 mAbs | Melanoma | CRITERIA | anti-CTLA-4 mAbs | THERAPY | ONCOLOGY | SAFETY | serum biomarkers | melanoma | anti-PD-1 mAbs | NIVOLUMAB | EXPRESSION | Original articles
Journal Article
Oncotarget, ISSN 1949-2553, 04/2019, Volume 10, Issue 31, pp. 2947 - 2958
Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a... 
Breast cancer | Anti-CTLA-4 | Immunotherapy | Radiation
Journal Article
Frontiers in Immunology, ISSN 1664-3224, 2014, Volume 5, Issue MAY
To improve the efficacy of immunotherapy for cancer and autoimmune diseases, recent ongoing and completed clinical trials have focused on specific targets to... 
Autoimmune disease | Anti-PD-1 | Tumor immunity | Immune-checkpoint inhibitor | Anti-CTLA-4 | tumor immunity | anti-CTLA-4 | autoimmune disease | anti-PD-1 | immune-checkpoint inhibitor
Journal Article
Cell, ISSN 0092-8674, 11/2019, Volume 179, Issue 5, pp. 1177 - 1190.e13
Immune checkpoint therapy (ICT) shows encouraging results in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) but still... 
bone metastases | castration-resistant prostate cancer | anti-CTLA-4 | TGF-β blockade | anti-PD-1 | Th1 subset
Journal Article
Science Translational Medicine, ISSN 1946-6234, 07/2018, Volume 10, Issue 450, p. 2DUMMY
Combination anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) therapy promotes antitumor immunity and provides... 
MEDICINE, RESEARCH & EXPERIMENTAL | LUNG-CANCER | EXPRESSION ANALYSIS | IMMUNE CHECKPOINT BLOCKADE | ANTI-CTLA-4 THERAPY | T-CELL-ACTIVATION | ACQUIRED-RESISTANCE | TUMOR | MECHANISMS | CLINICAL-RESPONSE | IPILIMUMAB | CELL BIOLOGY
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 1 - 3
Journal Article
Journal Article
Journal Article